Reduction in hospitalized women with pelvic inflammatory disease in Oslo over the past decade

Acta Obstetricia et Gynecologica Scandinavica

Volumn 84, Issue 3, 2005, Pages 290-296

  Sørbye, Ingvil Krarup ^a,b   Jerve, Fridtjof ^a   Staff, Anne Cathrine ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b NONE   (Netherlands)

Author keywords

Epidemiology; Pelvic inflammatory disease; Salpingitis; Tuboovarian abscess

Indexed keywords

CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; GONORRHEA; HOSPITALIZATION; HUMAN; MEDICAL RECORD; NEISSERIA GONORRHOEAE; NORWAY; OVARY INFLAMMATION; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; REVIEW; SALPINGITIS; TUBOOVARIAN ABSCESS;

ABSCESS; ADOLESCENT; ADULT; AGED; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; FOLLOW-UP STUDIES; GONORRHEA; HOSPITALIZATION; HUMANS; INTRAUTERINE DEVICES; LENGTH OF STAY; MIDDLE AGED; NEISSERIA GONORRHOEAE; NORWAY; OOPHORITIS; PELVIC INFLAMMATORY DISEASE; SALPINGITIS;

EID: 14744297339     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0001-6349.2005.00509.x     Document Type: Review

References (15)

1. Westrøm L. Incidence, prevalence and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol 1980; 138: 880-92.
2. Landers DV, Sweet RL. Tubo-ovarian abscess: contemporary approach to management. Rev Infect Dis 1983; 5: 876-84.
3. McNeeley SG, Hendrix SL, Mazzoni MM, Kmak DC, Ransom SB. Medically sound, cost-effective treatment for pelvic inflammatory disease and tuboovarian abscess. Am J Obstet Gynecol 1998; 178: 1272-8.
4. Kamwendo F, Forslin L, Bodin L, Danielsson D. Decreasing incidences of gonorrhoea- and chlamydia-associated acute pelvic inflammatory disease. Sex Transm Dis 1996; 5: 384-91.
5. Bjartling C, Osser S, Persson K. The frequencies of salpingitis and ectopic pregnancies as epidemiologic markers of Chlamydia trachomatis. Acta Obstet Gynecol Scand 2000; 79: 123-8.
6. Stray-Pedersen B. Prevention of sexually transmitted diseases. The Norwegian experience. Contracept Fertil Sex 1996; 24: 213-7.
7. International statistical classification of diseases and related health problems, 9th revision. Geneva: World Health Organization, 1987.
8. International statistical classification of diseases and related health problems, 10th revision. Geneva: World Health Organization, 1992.
9. Centre for Disease Control. Pelvic inflammatory disease: guidelines for prevention and management. Morbidity Mortality Weekly Report 1991; 40: 1-25.
10. Reljic M, Gorisek B. C-reactive protein and the treatment of pelvic inflammatory disease. Int J Gynaecol Obstet 1998; 60: 143-50.
11. Jacobson L, Westrøm L. Objectivized diagnosis of acute pelvic inflammatory disease. Am J Obstet Gynecol 1969; 105: 1088-98.
12. Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL et al. Hormonal and barrier contraception and risk of upper genital tract disease in the PID evaluation and clinical health (PEACH) study. Am J Obstet Gynecol 2001; 1: 121-7.
13. Grimes DA, Schulz FK. Antibiotic prophylaxis for intrauterine contraceptive device, insertion (Cochrane Review). In: The Cochrane Library, Issue 1. Chichester, UK: John Wiley & Sons, Ltd, 2004.
14. Skjeldestad FE. Choice of contraceptive modality by women in Norway. Acta Obstet Gynecol Scand 1994; 73: 48-52.
15. Cohen CR, Manhart LE, Bukusi EA, Astete S, Brunham RC, Holmes KK et al. Association between Mycoplasma genitalium and acute endometritis. Lancet 2002; 359: 765-6.